COMPANY:

Telogenomics

"Telo Genomics Corp...is pleased to announce that its application to the IPON program (Intellectual Property Ontario) was approved...The most recent patent applications filed by Telo support intellectual property protection of its flagship product for smoldering multiple myeloma TeloViewSMM."

"Telo Genomics Corp...is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study...Telo’s MRD assays are being evaluated utilizing Adaptive Biotechnologies’ clonoSEQ assay technology as a component of Telo’s ongoing MRD clinical trial, TELO-DMRD (NCT05530096), being conducted with McGill University, Montreal, Canada."

"Telo Genomics Corp...is pleased to announce that the US Centres of Medicare & Medicaid Services (CMS) which regulates the medical laboratories in the USA, has awarded Telo its Clinical Laboratory Improvement Amendment ('CLIA') certificate of registration, as a certified medical clinical laboratory. Telo’s registration is within the international stream of CLIA."

"Telo Genomics Corp...is pleased to announce that the College of American Pathologists (CAP) has recently accepted Telo Genomics’ submission to add Telo’s test for smoldering multiple myeloma (SMM), TeloViewSMM, as a Laboratory Developed Test (LDT) on Telo’s-CAP approved menu of clinical tests."

"Telo Genomics Corp...is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place in Chicago, USA between May 30-June 4, 2024."

"Telo Genomics Corp...is thrilled to announce that the manuscript titled, 'Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma' was accepted for publication in the American Journal of Hematology. The article describes the significant results achieved with Telo’s prognostic test for smoldering multiple myeloma (TeloViewSMM)."

"Telo Genomics Corp...is pleased to announce that the Company has signed a collaboration agreement with Emery Pharma ('Emery'). Emery is a full-service contract research organization (CRO) offering biologic drug development support and analytical characterization, and this agreement will facilitate its collaboration with Telo in providing a more comprehensive service."

"Telo Genomics Corp...is pleased to announce that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to TELO’s laboratory at the MaRS Center in Toronto, Canada; this is based on over a year of diligent preparation, and the results of a recent on-site inspection as part of the CAP’s Accreditation Programs. Recognized for rigorous and robust standards, and as one of the world’s most prestigious certifying bodies - CAP accreditation elevates quality and mitigates risk, and is an important contribution to improved patient outcomes."

"Telo Genomics Corp...is pleased to announce that patient recruitment for its minimal residual disease ('MRD') clinical trial has been initiated, with several patient samples received and processed to date. Also, due to institutional interest and to accelerate the study, Telo and its collaborators at the Jewish General Hospital and McGill University have expanded the study to include three additional prominent hospitals in the Montreal area."